CooperSurgical Inc has signed an agreement to acquire Teva Pharmaceutical Industries Ltd's PARAGARD (intrauterine copper contraceptive) for $1.1bn in cash.
The deal will enable CooperSurgical to repay term loan debt and reinforce its central nervous system (CNS) in addition to its respiratory business areas.
CooperSurgical is a medical and surgical products provider based in the US, while Teva is an Israeli pharmaceutical company.
Chinese firm Basecare Medical Device Co Ltd has secured CNY100m ($15.34m) in a series B funding round.
The company plans to use the funds towards the development of third-generation test-tube baby technology.
SPR Therapeutics LLC has secured $25m in a series C venture funding round led by a family office and Frontcourt Ventures.
The US-based company plans to use the funds towards the commercialisation of its FDA-cleared SPRINT peripheral nerve stimulation (PNS) system and additional research.
Cheetah Medical Inc has secured an additional $11.76m in a series C funding round, bringing the total funding to $40.61m. The company previously raised $14.4m in an extended series C financing round in February.
The US-based firm intends to use the stocks towards the expansion of its business in the country.